Coronavirus

Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections

BERKELEY HEIGHTS, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

3 years ago

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

$500 Million Upfront Payment to Activate the Partnership for IvonescimabMenlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06,…

3 years ago

Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board

Professor Dr. med. Matthias Dobbelstein Professor Dr. med. Matthias DobbelsteinJerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals…

3 years ago

Sernova Corp. Announces CEO Succession Plan and Expanded Management Team

The Company is recruiting a new CEO for its next stage of growth - Dr. Toleikis, President and CEO, to…

3 years ago

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining the ability of oral vaccine…

3 years ago

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS DayBETHLEHEM, Pa., Dec. 01, 2022…

3 years ago

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy…

3 years ago

Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022

New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical…

3 years ago

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless…

3 years ago